7 Schwarz T, Dubin G, Human Papillomavirus 16/18 L1 AS04 Virus – Like Particle Cervical Cancer vaccine are immunogenic and well tolerated 18 months after vaccination in women well up to the age 55 Presented at ASCO Annual Clinical Meeting June 2007.
CervarixTM, the cervical cancer vaccine from GSK has granted a license by the Therapeutic Goods Administration in Australia for the prevention of cervical cancer and precancerous lesions with the most common cancer-causing human papillomavirus types associated. CervarixTM now is approved in Australia for use in old women aged 10 to 45 years. This is the first major market license for CervarixTM, GSK cervical cancer vaccine.HIV prevalence of Mozambique over recent years in recent years, and about 16 percent of adults in the country is HIV positive, that Independent Online reports (Independent Online J. A free service of The Henry J. Publish. Kaiser Family Foundation.